Increased Level of Interleukin 6 Associates With Increased 90‐Day and 1‐Year Mortality in Patients With End‐Stage Liver Disease

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Clinical Gastroenterology and Hepatology

• Publication date

  2017-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.cgh.2017.09.017PMID 28919544
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• IL-6 significantly correlates with p-STAT3 expression and presents high variceal bleeding with mortality in cirrhotic patients: A cross-sectional study.

  2017cited by this paper
• Prediction Models for Gastrointestinal and Liver Diseases: Too Many Developed, Too Few Validated.

  2016influential reference
• IL-6 pathway in the liver: From physiopathology to therapy.

  2016cited by this paper
• Prognostic value of C-reactive protein in cirrhosis: external validation from the CANONIC cohort

  2016cited by this paper
• Toward sustainable and effective control: Experience of China Ebola Treatment Center in Liberia

  2016cited by this paper
• Prognosis and Biomarkers in Acute-on-Chronic Liver Failure

  2016cited by this paper
• Current Status of Liver Allocation in the United States.

  2016cited by this paper
• Use of serum sodium for liver transplant graft allocation: A decade in the making, now is it ready for primetime?

  2015cited by this paper
• Prognostic value of C‐reactive protein levels in patients with cirrhosis

  2015cited by this paper
• The usefulness of C-reactive protein and neutrophil-to-lymphocyte ratio for predicting the outcome in hospitalized patients with liver cirrhosis

  2015cited by this paper
• IL-6, through p-STAT3 rather than p-STAT1, activates hepatocarcinogenesis and affects survival of hepatocellular carcinoma patients: a cohort study

  2015cited by this paper
• Extended leukocyte differential count and C-reactive protein in septic patients with liver impairment: diagnostic approach to evaluate sepsis in intensive care unit.

  2015cited by this paper
• Interleukins in chronic liver disease: lessons learned from experimental mouse models

  2014cited by this paper
• Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure.

  2014cited by this paper
• Liver regeneration.

  2012cited by this paper
• C-reactive protein predicts short-term mortality in patients with cirrhosis.

  2012cited by this paper
• pROC: an open-source package for R and S+ to analyze and compare ROC curves

  2011cited by this paper
• Model for end-stage liver disease: end of the first decade.

  2011cited by this paper
• The systemic inflammatory response syndrome in cirrhotic patients: relationship with their in-hospital outcome.

  2009cited by this paper
• Infection and inflammation in liver failure: two sides of the same coin.

  2009cited by this paper
• The model for end‐stage liver disease (MELD)

  2007cited by this paper
• Interleukin‐6 inhibits oxidative injury and necrosis after extreme liver resection

  2007cited by this paper
• Model for end‐stage liver disease score and systemic inflammatory response are major prognostic factors in patients with cirrhosis and acute functional renal failure

  2007cited by this paper
• Paradoxical effects of short‐ and long‐term interleukin‐6 exposure on liver injury and repair

  2006cited by this paper
• Liver regeneration

  2006cited by this paper
• Interleukin 6/gp130‐dependent pathways are protective during chronic liver diseases

  2003cited by this paper
• Model for end-stage liver disease (MELD) and allocation of donor livers.

  2003cited by this paper
• MELD and PELD: Application of survival models to liver allocation

  2001cited by this paper
• Combined interleukin 6 and soluble interleukin 6 receptor accelerates murine liver regeneration.

  2000cited by this paper
• Procalcitonin behaves as a fast responding acute phase protein in vivo and in vitro

  2000influential reference
• Liver regeneration induced by a designer human IL‐6/ sIL‐6R fusion protein reverses severe hepatocellular injury

  2000cited by this paper
• Interleukin-6 and soluble interleukin-6 receptor: direct stimulation of gp130 and hematopoiesis.

  1998influential reference
• INTERLEUKIN‐6: A SENSITIVE PARAMETER FOR THE EARLY DIAGNOSIS OF NEONATAL BACTERIAL INFECTION: 480

  1997influential reference
• Liver Failure and Defective Hepatocyte Regeneration in Interleukin-6-Deficient Mice

  1996cited by this paper
• Interleukin-6: a sensitive parameter for the early diagnosis of neonatal bacterial infection.

  1994cited by this paper
• Elevated plasma interleukin-6 and increased severity and mortality in alcoholic hepatitis.

  1991cited by this paper
• Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach.

  1988cited by this paper
• Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells.

  1987cited by this paper
• THE LIVER AS THE SITE OF C-REACTIVE PROTEIN FORMATION

  1966cited by this paper

• Serum Interleukin-6 Levels may be a Key Determinant of 6-week Further Decompensation Risk in Patients With Cirrhosis and Acute Variceal Bleed: A Proof of Concept Study.

  2025cites this paper
• Interaction of inflammation and portal hypertension in cirrhosis progression

  2025cites this paper
• Circulating Cell‐Free Mitochondrial DNA as a Prognostic Biomarker in Patients With HBV‐Related Acute‐on‐Chronic Liver Failure

  2025cites this paper
• BLOOD PLASMA СYTOKINE LEVELS IN PATIENTS WITH CHRONIC VIRAL HEPATITIS B STAGE-DEPENDENT LIVER FIBROSIS

  2025cites this paper
• Assessment of Interleukin-6 Levels in Patients with Liver Cirrhosis and its Correlation with Disease Severity and Mortality

  2025cites this paper
• Serum pro‐inflammatory cytokine interleukin‐6 level is predictive of further decompensation and mortality in liver cirrhosis

  2025cites this paper
• Association between neutrophil percentage to albumin ratio and short term prognosis of acute on chronic liver failure treated with artificial liver support system

  2025cites this paper
• Elevated CD169 expressing monocyte/macrophage promotes systemic inflammation and disease progression in cirrhosis

  2024cites this paper
• Inflammation remains a dynamic component of portal hypertension in regressive alcohol‐related cirrhosis

  2024cites this paper
• A combined association of alanine aminotransferase, aspartate transaminase and bilirubin with sleep duration in aged 16–85 years (2005–2010)

  2024cites this paper
• Association between systemic immune inflammation index and short term prognosis of acute on chronic liver failure

  2024cites this paper
• The Impact of Liver Failure on the Immune System

  2024cites this paper
• The double-edged effects of IL-6 in liver regeneration, aging, inflammation, and diseases

  2024cites this paper
• The Renin–Angiotensin System in Liver Disease

  2024cites this paper
• Are Selected Cytokines and Epstein–Barr Virus DNA Load Predictors of Hepatological Complications of Epstein–Barr Virus Infection in Children?

  2023cites this paper
• The challenges and potential in developing microRNA associated with regeneration as biomarkers to improve prognostication for liver failure syndromes and hepatocellular carcinoma

  2023cites this paper
• Comparison of Inflammatory Cytokine Levels in Hepatic and Jugular Veins of Patients with Cirrhosis

  2023cites this paper
• A novel score of IL-13 and age predicts 90-day mortality in severe alcohol-associated hepatitis: A multicenter plasma biomarker analysis

  2023cites this paper
• A new machine-learning-based prediction of survival in patients with end-stage liver disease

  2023cites this paper
• Acute-on-chronic liver failure (ACLF) in 2022: have novel treatment paradigms already arrived?

  2022cites this paper
• Liver Stromal Cells Restrict Macrophage Maturation and Stromal IL-6 Limits the Differentiation of Cirrhosis-linked Macrophages.

  2022cites this paper
• Diagnostic and prognostic significance of cell death markers in patients with cirrhosis and acute decompensation

  2022cites this paper
• Identification and Analysis of Gut Microbiota and Functional Metabolism in Decompensated Cirrhosis with Infection

  2022cites this paper
• Dynamics in Circulating y -55Proinflammatory Biomarkers for Prognostic Assessment of Patients With Advanced HCC – A Substudy From the SORAMIC Trial

  2022cites this paper
• A practical nomogram based on serum interleukin-6 for the prognosis of liver failure

  2022cites this paper
• Oxidative stress-induced growth inhibitor 1 in alcohol-induced liver cirrhosis.

  2021cites this paper
• Proprotein convertase subtilisin/kexin type 9 (PCSK9) levels are not associated with severity of liver disease and are inversely related to cholesterol in a cohort of thirty eight patients with liver cirrhosis

  2021cites this paper
• Presepsin as a biomarker of inflammation and prognosis in decompensated liver disease.

  2021cites this paper
• Cystatin C and interleukin‐6 for prognosticating patients with acute decompensation of cirrhosis

  2021cites this paper
• Prognostic value of baseline interleukin 6 levels in liver decompensation and survival in HCC patients undergoing radioembolization

  2021cites this paper
• Modeling alcohol-associated liver disease in a human Liver-Chip

  2021cites this paper
• Raman spectroscopy on blood serum samples of patients with end-stage liver disease

  2021cites this paper
• Elevated serum levels of methylglyoxal are associated with impaired liver function in patients with liver cirrhosis

  2021cites this paper
• Systemic pharmacology understanding of the key mechanism of Sedum sarmentosum Bunge in treating hepatitis

  2020cites this paper
• Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality.

  2020cites this paper
• Update on diagnosis and management of sepsis in cirrhosis: Current advances

  2020cites this paper
• High levels of serum interleukin-6 increase mortality of hepatitis B virus-associated acute-on-chronic liver failure

  2020cites this paper
• Systemic pharmacology understanding of the key mechanism of Sedum sarmentosum Bunge in treating hepatitis

  2020cites this paper
• Modeling alcoholic liver disease in a human Liver-Chip

  2020cites this paper
• Abstinent patients with alcohol use disorders show an altered plasma cytokine profile: Identification of both interleukin 6 and interleukin 17A as potential biomarkers of consumption and comorbid liver and pancreatic diseases

  2020cites this paper
• Anemia and Systemic Inflammation Rather than Arterial Circulatory Dysfunction Predict Decompensation of Liver Cirrhosis

  2020influential citation
• Liver transplantation for acute-on-chronic liver failure.

  2020cites this paper
• Diagnostic and prognostic role of presepsin in patients with cirrhosis and bacterial infection

  2020cites this paper
• A novel STAT3 inhibitor, STX-0119, attenuates liver fibrosis by inactivating hepatic stellate cells in mice.

  2019cites this paper
• Effects of liver ischemia-reperfusion injury on respiratory mechanics and driving pressure during orthotopic liver transplantation.

  2019cites this paper
• Raised serum Interleukin‐6 identifies patients with liver cirrhosis at high risk for overt hepatic encephalopathy

  2019cites this paper
• Interleukin‐6 levels drop after a 12 week long physiotherapeutic intervention in patients with Achilles tendinopathy—a pilot study

  2019cites this paper
• Copeptin – a biomarker of short-term mortality risk (7 days) in patients with end-stage liver disease

  2019cites this paper
• Predictive Role of Serum Cytokine Profiles in Acute Kidney Injury after Living Donor Liver Transplantation

  2018cites this paper
• The impact of serum cytokines in the development of early allograft dysfunction in living donor liver transplantation

  2018cites this paper
• Management of Infectious Complications Associated with Acute-on-Chronic Liver Failure

  2018cites this paper
• Immunodysfunction in Acute-on-Chronic Liver Failure

  2018cites this paper
• More Than Meets the Eye in Using Interleukin 6 as a Marker of Inflammation and Prognostic Factor for Patients With Cirrhosis.

  2017cites this paper